GeneDx (WGS) - 2025 Q4 - Annual Results

Revenue Growth - GeneDx reported preliminary full year 2025 revenues of approximately $427 million, representing a 41% year-over-year increase[7] - For the fourth quarter of 2025, revenues were approximately $121 million, an increase of 27% year-over-year[7] - Exome and genome revenues for full year 2025 were approximately $360 million, up 54% year-over-year (58% excluding a one-time 2024 benefit)[7] - The company expects full year 2026 revenues to be between $540 million and $555 million, with exome and genome growth projected at 33% to 35%[9] Patient Volume and Access - GeneDx accessioned more than 30,000 patients in the fourth quarter of 2025, demonstrating a volume growth rate of 34.3% year-over-year[3] - GeneDx secured Medicaid coverage for exome and genome sequencing in 8 new states, increasing total coverage to 37 states[13] Profitability and Margins - The adjusted gross margin for full year 2025 was approximately 71%, with a similar margin expected for the fourth quarter[12] Product and Service Expansion - GeneDx launched GeneDx Infinity™, the world's largest rare disease genomic dataset, which includes nearly 1 million exomes and genomes[13] - The company expanded into general pediatrics and prenatal diagnostics, enhancing its market reach and service offerings[13] Leadership Changes - The company appointed new leadership, including Dr. Linda Genen as Chief Medical Officer, to support its growth strategy[16]